The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|42|6555-6564

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.42, 2014-12, pp. : 6555-6564

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Toll-like receptor 9 agonists as cancer therapeutics

By Holtick Udo   Scheulen Max E   von Bergwelt-Baildon Michael S   Weihrauch Martin R  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 361-372

Informa Healthcare

Access to resources Recommend Favorite

Exogenous siRNA Mediates Sequence-Independent Gene Suppression by Signaling through Toll-Like Receptor 3

By  

Cells Tissues Organs, Vol. 177, Iss. 3, 2004-09 ,pp. : 132-138

Karger

Access to resources Recommend Favorite

Modifying Toll-like Receptor 9 Signaling for Therapeutic Use

By  

Mini Reviews in Medicinal Chemistry, Vol. 6, Iss. 3, 2006-03 ,pp. : 287-291

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Interactions in Interleukin and Toll-like Receptor Signaling Pathways

By  

Current Pharmaceutical Design, Vol. 20, Iss. 8, 2014-03 ,pp. : 1244-1258

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Toll-Like Receptor Signaling Pathways for Design of Novel Immune Therapeutics

By  

Current Drug Discovery Technologies, Vol. 5, Iss. 1, 2008-03 ,pp. : 29-38

Bentham Science Publishers

Access to resources Recommend Favorite